How effective is axitinib/axitinib in the treatment of kidney cancer? Clinical research and application analysis

Axitinib is a small molecule tyrosine kinase inhibitor that mainly acts on vascular endothelial growth factor receptor (VEGFR) and treats advanced renal cell carcinoma (RCC) by inhibiting tumor angiogenesis. In the past few years, axitinib has been widely used in the treatment of advanced renal cell carcinoma and has shown significant therapeutic effects in multiple clinical studies.

Clinical studies have shown that axitinib has shown good efficacy in the treatment of advanced renal cell carcinoma. In a global multi-center phase III clinical trial (AXIS trial) conducted in 2011, axitinib, as a second-line treatment drug, significantly prolonged progression-free survival (PFS) compared with traditional treatment options. In this study, patients who received axitinib had improved PFS by several months compared with patients who received other treatments, demonstrating the advantages of axitinib in drug-resistant renal cancer.

In addition to second-line treatment, axitinib can be used in combination with other immunotherapy drugs. For example, combined with Avelumab (Avelumab) for the first-line treatment of patients with advanced renal cell carcinoma, it can significantly improve the patient's overall survival (OS) and progression-free survival (PFS). The effect of this combination therapy has been widely verified clinically and provides patients with more effective treatment options.

In addition, axitinib can also be used in combination with pembrolizumab, another immune checkpoint inhibitor, to further enhance the anti-tumor effect. Research shows that combined treatment with axitinib and pembrolizumab can help patients overcome drug resistance and achieve better treatment outcomes.

However, the therapeutic effect of axitinib is not applicable to all patients, and some patients may experience side effects, such as high blood pressure, oral ulcers, fatigue, etc. These side effects require careful monitoring and management during treatment.

Reference materials:https://en.wikipedia.org/wiki/Axitinib